Amgen Settles Patent Suit With Amneal on Neupogen Biosimilar

Nov. 27, 2019, 6:27 PM

Amgen had claimed that Amneal and Kashiv’s proposed biosimilar version of Neupogen infringed patents for the cancer drug.

  • No details were provided in notice of agreement, approved Monday in federal court in Newark, New Jersey
  • Neupogen, a white blood cell booster, has been on the market since 1991
  • Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
  • Kashiv and Amneal have a license and commercialization agreement in which Kashiv handles development, regulatory filings and manufacturing, and Amneal is responsible for marketing, selling and pricing the Neupogen biosimilar
  • Neupogen had U.S. sales of $137 million...

To read the full article log in.

Learn more about A Bloomberg Law subscription.